Helen Ljungdahl Round, Acarix President & CEO presents at Redeye Investor Forum
On May 4th at 14.40 Helen Ljungdahl Round, Acarix President & CEO, presents the latest developments in the company at the Redeye In...
Acarix to present at the 2023 Aktiespararna Share Day in Stockholm
Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces that the company will present at the 2023 Aktiespararna Share ...
The exercise period for Acarix warrants of series 2022:U begins today
In December 2022, Acarix AB (publ) (“Acarix” or the “Company”) carried out a rights issue of shares and warrant...
Acarix AB’s Annual Report 2022
Acarix, a leader in acoustic and AI-based cardiac diagnostics, today announces that the Annual Report for 2022 is available as a pdf on...
Notice of Annual General Meeting in Acarix AB
The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the annual general meeting to be held on T...
Acarix carries out a directed share issue amounting to approximately SEK 9.5 million
THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, ...
Acarix accelerates US commercialization into 30 additional states
Acarix, a leader in acoustic and AI-based cardiac diagnostics, today announced a strategic sales partnership with CompleMed, LLC, a nat...
Study published in Heart strengthens diagnostic value of Acarix CADScor System
Acarix, a leader in acoustic and AI-based cardiac diagnostics, today announced the release of a new study published in the March 2023 i...
Acarix presents at Redeye: Commercialization Seminar
On March 7 at 10.30 CET Helen Ljungdahl Round, CEO of Acarix, presents the latest developments in the company at Redeye.The presentatio...
Acarix to showcase at the 2023 ACC congress
Acarix, a leader in acoustic and AI-based cardiac diagnostics, will demonstrate the value of its CADScor System during the American Col...
Acarix receives breakthrough order from US Veterans Health Administration
Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces today the first order from the US Veterans Health Administrati...
Acarix AB (publ) publishes Year-End Report 2022
Strategic shift towards full commercial focus on the US market now in placeAs we sum up 2022, it becomes clear that Acarix has in a sho...